Design and baseline characteristics for the ACE Inhibitor After Anthracycline (AAA) study of cardiac dysfunction in long-term pediatric cancer survivors Journal Article
| Authors: | Silber, J. H.; Cnaan, A.; Clark, B. J.; Paridon, S. M.; Chin, A. J.; Rychik, J.; Hogarty, A. N.; Cohen, M. I.; Barber, G.; Rutkowsky, M.; Kimball, T. R.; Delaat, C.; Steinherz, L. J.; Zhao, H.; Tartaglione, M. R. |
| Article Title: | Design and baseline characteristics for the ACE Inhibitor After Anthracycline (AAA) study of cardiac dysfunction in long-term pediatric cancer survivors |
| Abstract: | Purpose. The ACE Inhibitor After Anthracycline (AAA) study is a randomized, double-blind, controlled clinical trial comparing enalapril with placebo to determine whether treatment can slow the progression of cardiac decline in patients who screen positive for anthracycline cardiotoxicity. Methods: The primary outcome measure is the rate of decline, over time, in maximal cardiac index (in liters per minute per meters squared) at peak exercise; the secondary outcome measure is the rate of increase in left ventricular end `systolic wall stress (in grams per centimeters squared). Patients >2 years off therapy and <4 years from diagnosis, aged 8 years and older, were eligible if they had received anthracydines and had at least one cardiac abnormality identified at any time after anthracycline exposure. Results: A total of 135 patients were randomized to enalapril or placebo. Baseline characteristics were similar across treatment groups. Conclusions: The AAA study will provide important information concerning the efficacy of using angiotensin-converting enzyme inhibitors to offset the effects of late anthracydine cardiotoxicity. |
| Keywords: | adolescent; adult; cancer chemotherapy; cancer survival; child; controlled study; school child; child, preschool; major clinical study; clinical trial; disease course; drug efficacy; united states; research design; neoplasms; controlled clinical trial; heart disease; randomized controlled trial; exercise; mass screening; age factors; drug effect; algorithms; childhood cancer; hypotension; infant; disease progression; multicenter study; cardiotoxicity; drug response; outcomes research; anthracycline; screening test; double blind procedure; double-blind method; anthracyclines; dipeptidyl carboxypeptidase inhibitor; heart index; statistics, nonparametric; drug induced disease; drug exposure; placebos; angioneurotic edema; heart diseases; vertigo; enalapril; angiotensin-converting enzyme inhibitors; heart function tests; humans; human; male; female; priority journal; article; heart left ventricle wall; heart stress |
| Journal Title: | American Heart Journal |
| Volume: | 142 |
| Issue: | 4 |
| ISSN: | 0002-8703 |
| Publisher: | Mosby Elsevier |
| Date Published: | 2001-10-01 |
| Start Page: | 577 |
| End Page: | 585 |
| Language: | English |
| DOI: | 10.1067/mhj.2001.118115 |
| PUBMED: | 11579345 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Export Date: 21 May 2015 -- Source: Scopus |
